Oncology · Pancreatic Ductal Adenocarcinoma
The findings from the trial indicate that localized therapies like SBRT and IL-12 can significantly alter hematopoiesis, which may have implications for patient outcomes in PDAC. This shift towards localized treatment approaches could reshape clinical strategies and necessitate further investigation into their long-term effects.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 6/22/2026, 6:32:45 AM
Assessment confidence: 46% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.
The findings from the trial indicate that localized therapies like SBRT and IL-12 can significantly alter hematopoiesis, which may have implications for patient outcomes in PDAC. This shift towards localized treatment approaches could reshape clinical strategies and necessitate further investigation into their long-term effects. Assessment grounded in 19 ranked evidence items (1 high-relevance).
The strongest clinical anchor is Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Pancreatic Ductal Adenocarcinoma, 0 regulatory and 4 competitive items passed relevance filtering for SBRT. If localized therapies prove more effective than traditional systemic treatments, they could capture a larger market share in PDAC management, impacting revenue streams for companies involved in oncology.
The most relevant competitive pressure comes from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC (Humanexa Signals) — sponsor/company relevance (pfizer). Secondary pressure from Study Optimizes Immunotherapy for Pancreatic Adenocarcinoma Treatment. These findings suggest that localized therapies may offer advantages over systemic treatments, potentially reshaping approaches in PDAC management.
Regulatory risk is concentrated around The observed effects on bone marrow and hematopoiesis may require additional regulatory scrutiny regarding safety and efficacy profiles for new localized therapies in PDAC..
No evidence in this category.
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceTargeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceThe Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceIntestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceTesting the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceSintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceTesting the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceAn Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourcePfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalsmedium relevance
Sponsor/company relevance (Pfizer)
Study Optimizes Immunotherapy for Pancreatic Adenocarcinoma Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment
NCI's MATCH Trial Evaluates Genetic Testing for Targeted Therapy in Advanced Cancers
Humanexa Signalsmedium relevance
Moderate corpus alignment
Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment
Local delivery of SBRT and IL-12 to murine PDAC tumors modulates hematopoiesis.
PubMedhigh relevance
Entity match (sbrt)
FDA document
View sourceThe regulatory roles of non-coding RNAs in aerobic glycolysis and therapeutic potential in pancreatic ductal adenocarcinoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceOpsonization and timing as key determinants of MBTA immunotherapy efficacy in pancreatic adenocarcinoma and recurrence treatment.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceCombination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceDectin-1 signaling promotes Galectin-3 shedding and expansion of immunosuppressive CD71+ erythroid cells in breast cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceKnowledge mapping and research trends of chimeric antigen receptor T-cell immunotherapy in breast cancer: A bibliometric and visual analytics study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceSelf-perceived learning outcomes of academic detailing discussing rational therapy with proton pump inhibitors among general practitioners in Norway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe findings from the trial indicate that localized therapies like SBRT and IL-12 can significantly alter hematopoiesis, which may have implications for patient outcomes in PDAC. This shift towards localized treatment approaches could reshape clinical strategies and necessitate further investigation into their long-term effects.
If localized therapies prove more effective than traditional systemic treatments, they could capture a larger market share in PDAC management, impacting revenue streams for companies involved in oncology.
The observed effects on bone marrow and hematopoiesis may require additional regulatory scrutiny regarding safety and efficacy profiles for new localized therapies in PDAC.
Monitor further studies on the long-term immunological effects of localized SBRT/IL-12 therapy in PDAC.
Track for follow-up milestones; no immediate action required.